S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ALPN

Alpine Immune Sciences Stock Forecast, Price & News

$11.43
-0.57 (-4.75%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.12
$11.83
50-Day Range
$9.59
$13.75
52-Week Range
$7.87
$16.37
Volume
23,950 shs
Average Volume
109,965 shs
Market Capitalization
$333.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.55
30 days | 90 days | 365 days | Advanced Chart
Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.


Alpine Immune Sciences logo

About Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Headlines

3 Stocks Seeing Heavy Net Insider Buying
November 15, 2021 |  insidertrades.com
Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Employees
57
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.34 million
Book Value
$4.20 per share

Profitability

Net Income
$-27.94 million
Net Margins
-169.03%
Pretax Margin
-168.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
12,331,000
Market Cap
$333.98 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/17/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

205th out of 1,391 stocks

Pharmaceutical Preparations Industry

84th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

Is Alpine Immune Sciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alpine Immune Sciences stock.
View analyst ratings for Alpine Immune Sciences
or view top-rated stocks.

How has Alpine Immune Sciences' stock price been impacted by Coronavirus?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPN shares have increased by 292.8% and is now trading at $11.43.
View which stocks have been most impacted by COVID-19
.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Alpine Immune Sciences
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of $0.01 by $0.56. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 58.85% and a negative net margin of 169.03%.
View Alpine Immune Sciences' earnings history
.

What price target have analysts set for ALPN?

2 equities research analysts have issued 12 month price objectives for Alpine Immune Sciences' shares. Their forecasts range from $19.00 to $21.00. On average, they anticipate Alpine Immune Sciences' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 75.0% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences
or view top-rated stocks among Wall Street analysts.

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Mitchell H. Gold, Executive Chairman & Chief Executive Officer (LinkedIn Profile)
  • Stanford L. Peng, President & Head-Research & Development
  • Thaedra Thullberry, Finance Director
  • James Paul Rickey, Chief Financial Officer, Secretary & Senior VP
  • Wayne R. Gombotz, Chief Technology Officer

What other stocks do shareholders of Alpine Immune Sciences own?

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (6.65%), BlackRock Inc. (2.29%), Renaissance Technologies LLC (1.65%), Geode Capital Management LLC (0.81%), Ensign Peak Advisors Inc (0.30%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Alpine Immune Sciences stock include Decheng Capital China Life Sci, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends for Alpine Immune Sciences
.

Which major investors are selling Alpine Immune Sciences stock?

ALPN stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Deutsche Bank AG, Two Sigma Advisers LP, California State Teachers Retirement System, New York State Common Retirement Fund, and Renaissance Technologies LLC. Company insiders that have sold Alpine Immune Sciences company stock in the last year include Mitchell Gold, and Orbimed Advisors Llc.
View insider buying and selling activity for Alpine Immune Sciences
or view top insider-selling stocks.

Which major investors are buying Alpine Immune Sciences stock?

ALPN stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Two Sigma Investments LP, Ensign Peak Advisors Inc, HighVista Strategies LLC, Bank of New York Mellon Corp, Dimensional Fund Advisors LP, BlackRock Inc., and Barclays PLC. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Decheng Capital China Life Sci, Orbimed Advisors Llc, and Robert E Conway.
View insider buying and selling activity for Alpine Immune Sciences
or or view top insider-buying stocks.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $11.43.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences has a market capitalization of $333.98 million and generates $9.34 million in revenue each year. The biotechnology company earns $-27.94 million in net income (profit) each year or ($1.73) on an earnings per share basis.

How many employees does Alpine Immune Sciences have?

Alpine Immune Sciences employs 57 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

Where are Alpine Immune Sciences' headquarters?

Alpine Immune Sciences is headquartered at 188 East Blaine Street Suite 200, Seattle WA, 98102.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at (206) 788-4545, via email at [email protected], or via fax at 303-440-8399.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.